SPOTLIGHT: Stem cell trial approved


Osiris Therapeutics has been given a green light by the FDA to start a Phase II trial of Prochymal--a formulation of adult stem cells--for heart attack victims. Release

Suggested Articles

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.